Immune Thrombocytopenic Purpura Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Amgen, CSL Behring, Dova Pharmaceuticals.

(Las Vegas, Nevada, United States) DelveInsight's 'Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Immune Thrombocytopenia, historical and forecasted epidemiology as well as the Immune Thrombocytopenia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Download Sample Report to know more @https://www.delveinsight.com/sample-request/immune-thrombocytopenic-purpura-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Immune Thrombocytopenic Purpura Overview
Immune Thrombocytopenia previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. Immune Thrombocytopenia is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of Immune Thrombocytopenia stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur.
The two main types of Immune Thrombocytopenia are acute (short-term) and chronic (long term). Immune Thrombocytopenia is also categorized as primary and secondary based on the cause of the disease. Immune Thrombocytopenia in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary Immune Thrombocytopenia, whereas, secondary Immune Thrombocytopenia refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).

Click here to learn more about the Immune Thrombocytopenic Purpura Market Landscape @https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlight from Immune Thrombocytopenic Purpura Market Report
Assessments as per DelveInsight's analysts show that the majority of cases of Immune Thrombocytopenia are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of Immune Thrombocytopenia in 2017 in the United States.
DelveInsight's estimations suggest that the total prevalent population Immune Thrombocytopenia in the seven major markets was approximately 180,498 in 2017.
The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.
In 2017, there were around 63,725 prevalent cases and approximately 53,362 diagnosed prevalent cases of Immune Thrombocytopenia in the United States. Out of the total diagnosed cases, approximately 49,640 cases account for adult Immune Thrombocytopenia and approximately 3,723 cases were diagnosed prevalence population in children in 2017 in the United States.

Immune Thrombocytopenic Purpura Treatment Market
The major goal for the treatment of Immune Thrombocytopenia is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels. The management of Immune Thrombocytopenia varies widely and current international guidelines recommend several first- and second-line options, including some medicinal products that have not been approved in the EU for this particular condition. First-line treatment options include corticosteroids, intravenous immunoglobulin (IVIg) and intravenous anti-D immunoglobulin (the latter only for non-splenectomized Rhesus-D positive patients). Patients who fail to respond or who relapse face the options of treatment with second-line drug therapy or splenectomy but there is no clear evidence to support the best approach. Splenectomy can provide long term efficacy in around 60% of cases. Second-line drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vinca alkaloids and danazol, the immunosuppressants cyclophosphamide, azathioprine, cyclosporine or mycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab

Learn more about the treatment market for Immune Thrombocytopenic Purpura @https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Immune Thrombocytopenic Purpura Epidemiology Segmented by
Immune Thrombocytopenic Purpura prevalent cases
Immune Thrombocytopenic Purpura incident Cases
Immune Thrombocytopenic Purpura treatment cases
Immune Thrombocytopenic Purpura diagnosed cases

Immune Thrombocytopenic Purpura Dug Profile and Companies Covered
Octapharma USA
Amgen
CSL Behring
Dova Pharmaceuticals
Rigel Pharmaceuticals
Zenyaku Kogyo/Biogen Ide
And many others.

Learn more about the Key Companies and Emerging Therapies in the Immune Thrombocytopenic Purpura Market @https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Immune Thrombocytopenic Purpura Introduction
Executive Summary of Immune Thrombocytopenic Purpura
Disease Background and Overview
Immune Thrombocytopenic Purpura Epidemiology and patient population
Immune Thrombocytopenic Purpura Emerging Therapies
Immune Thrombocytopenic Purpura Market Outlook
Immune Thrombocytopenic Purpura Market Access and Reimbursement of Therapies
Immune Thrombocytopenic Purpura Market Drivers
Immune Thrombocytopenic Purpura Market Barriers
Appendix
Immune Thrombocytopenic Purpura Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Immune Thrombocytopenic Purpura Market Outlook report @ https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Immune Thrombocytopenic Purpura Pipeline Forecast
https://www.delveinsight.com/report-store/immune-thrombocytopenic-purpura-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.